ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis, MMV extend malaria drug pact

by Lisa M. Jarvis
June 27, 2016 | APPEARED IN VOLUME 94, ISSUE 26

As part of a broadened pact with the nonprofit Medicines for Malaria Venture, Novartis will lead the development of the antimalarial KAF156, currently in Phase IIb studies. KAF156 belongs to a new class of compounds called imidazolepiperazines, which are able to take down the parasite that causes malaria in both the liver and blood stage of its reproductive cycle. The compound has the potential to address multi-drug-resistant strains of the infection.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment